- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00327691
En studie for å bestemme graden av ytterligere reduksjon i CV-risiko ved å senke LDL under minimumsmålnivåer (TNT)
1. mai 2007 oppdatert av: Pfizer
Effekten av LDL-kolesterol, som senker utover de nåværende anbefalte minimumsmålene på tilbakefall av koronar hjertesykdom (CHD) hos pasienter med allerede eksisterende CHD
Hovedmålet med denne studien er å bestemme graden av ytterligere reduksjon i kardiovaskulær risiko som ble påført pasienter ved å senke deres LDL-C utover det nåværende aksepterte minimumsmålnivået for pasienter med allerede eksisterende CHD.
Sekundære mål inkluderer sikkerhetsprofilen til denne behandlingsstrategien, dens kostnadseffektivitet, effekt på andre aterosklerotiske relaterte hendelser og prosedyrer, og total dødelighet.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering
8600
Fase
- Fase 4
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
- Pfizer Investigational Site
-
-
-
-
New South Wales
-
St. Leonards, New South Wales, Australia, 2065
- Pfizer Investigational Site
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- Pfizer Investigational Site
-
Brisbane, Queensland, Australia, 4029
- Pfizer Investigational Site
-
Chermside, Queensland, Australia, 4032
- Pfizer Investigational Site
-
Greenslopes, Queensland, Australia, 4130
- Pfizer Investigational Site
-
Herston, Queensland, Australia, 4029
- Pfizer Investigational Site
-
Milton, Queensland, Australia, 4064
- Pfizer Investigational Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Pfizer Investigational Site
-
Bedford Park, South Australia, Australia, 5042
- Pfizer Investigational Site
-
-
Tasmania
-
Hobart, Tasmania, Australia, 7000
- Pfizer Investigational Site
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Pfizer Investigational Site
-
Parkville, Victoria, Australia, 3050
- Pfizer Investigational Site
-
Prahran, Victoria, Australia, 3181
- Pfizer Investigational Site
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Pfizer Investigational Site
-
-
-
-
-
Aalst, Belgia, 9300
- Pfizer Investigational Site
-
Antwerpen, Belgia, B-2020
- Pfizer Investigational Site
-
Genk, Belgia, 3600
- Pfizer Investigational Site
-
Genk, Belgia, B-3600
- Pfizer Investigational Site
-
Godinne, Belgia, 5530
- Pfizer Investigational Site
-
Leuven, Belgia, 3000
- Pfizer Investigational Site
-
Lommel, Belgia, 3920
- Pfizer Investigational Site
-
Neerpelt, Belgia, 3910
- Pfizer Investigational Site
-
-
-
-
-
Quebec, Canada, G1R 2J6
- Pfizer Investigational Site
-
-
Alberta
-
Calgary, Alberta, Canada, T2E 7C5
- Pfizer Investigational Site
-
Calgary, Alberta, Canada, T2N 4N1
- Pfizer Investigational Site
-
Edmonton, Alberta, Canada, T5R 4H5
- Pfizer Investigational Site
-
Edmonton, Alberta, Canada, T6G 2B7
- Pfizer Investigational Site
-
-
British Columbia
-
Nanaimo, British Columbia, Canada, V9S 2B8
- Pfizer Investigational Site
-
Vancouver, British Columbia, Canada, V6R 1Y6
- Pfizer Investigational Site
-
Victoria, British Columbia, Canada, V8T 5G4
- Pfizer Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1R9
- Pfizer Investigational Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Pfizer Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 3A7
- Pfizer Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Pfizer Investigational Site
-
London, Ontario, Canada, N6A 4G5
- Pfizer Investigational Site
-
Ottawa, Ontario, Canada, K1Y 4W7
- Pfizer Investigational Site
-
Sudbury, Ontario, Canada, P3E 1B8
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M5C 2T2
- Pfizer Investigational Site
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 5H6
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H3A 1A1
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H1T 1C8
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H2W 1R7
- Pfizer Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Pfizer Investigational Site
-
St-foy, Quebec, Canada, G1V 4G2
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Alabaster, Alabama, Forente stater, 35007
- Pfizer Investigational Site
-
Birmingham, Alabama, Forente stater, 35205-4785
- Pfizer Investigational Site
-
Birmingham, Alabama, Forente stater, 35213
- Pfizer Investigational Site
-
Birmingham, Alabama, Forente stater, 35294-2041
- Pfizer Investigational Site
-
Hoover, Alabama, Forente stater, 35216
- Pfizer Investigational Site
-
Montgomery, Alabama, Forente stater, 36117
- Pfizer Investigational Site
-
-
Arizona
-
Mesa, Arizona, Forente stater, 85202
- Pfizer Investigational Site
-
Mesa, Arizona, Forente stater, 85206
- Pfizer Investigational Site
-
-
California
-
Burbank, California, Forente stater, 91505
- Pfizer Investigational Site
-
Camp Pendleton, California, Forente stater, 92055
- Pfizer Investigational Site
-
Fresno, California, Forente stater, 93703
- Pfizer Investigational Site
-
La Jolla, California, Forente stater, 92037
- Pfizer Investigational Site
-
Loma Linda, California, Forente stater, 92354
- Pfizer Investigational Site
-
Los Angeles, California, Forente stater, 90048
- Pfizer Investigational Site
-
Los Angeles, California, Forente stater, 90017-2395
- Pfizer Investigational Site
-
Modesto, California, Forente stater, 95350
- Pfizer Investigational Site
-
Pasadena, California, Forente stater, 91105
- Pfizer Investigational Site
-
Rancho Mirage, California, Forente stater, 92270
- Pfizer Investigational Site
-
San Diego, California, Forente stater, 92134-3303
- Pfizer Investigational Site
-
San Francisco, California, Forente stater, 94143-0130
- Pfizer Investigational Site
-
San Francisco, California, Forente stater, 94143-0326
- Pfizer Investigational Site
-
Santa Rosa, California, Forente stater, 95403
- Pfizer Investigational Site
-
Stanford, California, Forente stater
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Pfizer Investigational Site
-
Denver, Colorado, Forente stater, 80220
- Pfizer Investigational Site
-
Denver, Colorado, Forente stater, 80218
- Pfizer Investigational Site
-
Denver, Colorado, Forente stater, 80203
- Pfizer Investigational Site
-
-
Connecticut
-
Bridgeport, Connecticut, Forente stater, 06610
- Pfizer Investigational Site
-
Hartford, Connecticut, Forente stater, 06102
- Pfizer Investigational Site
-
New Britain, Connecticut, Forente stater, 06053
- Pfizer Investigational Site
-
-
Delaware
-
Newark, Delaware, Forente stater, 19718
- Pfizer Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Forente stater, 20037
- Pfizer Investigational Site
-
-
Florida
-
Clearwater, Florida, Forente stater, 33756
- Pfizer Investigational Site
-
Gainsville, Florida, Forente stater, 32608
- Pfizer Investigational Site
-
Gainsville, Florida, Forente stater, 32610
- Pfizer Investigational Site
-
Hollywood, Florida, Forente stater, 33021
- Pfizer Investigational Site
-
Inverness, Florida, Forente stater, 34452
- Pfizer Investigational Site
-
Lakeland, Florida, Forente stater, 33805
- Pfizer Investigational Site
-
Miami, Florida, Forente stater, 33173
- Pfizer Investigational Site
-
Miami, Florida, Forente stater, 33176
- Pfizer Investigational Site
-
Ocala, Florida, Forente stater, 34474
- Pfizer Investigational Site
-
Orlando, Florida, Forente stater, 32803
- Pfizer Investigational Site
-
Port Charlotte, Florida, Forente stater, 33952
- Pfizer Investigational Site
-
Sarasota, Florida, Forente stater, 34239
- Pfizer Investigational Site
-
Stuart, Florida, Forente stater, 34996
- Pfizer Investigational Site
-
Tamarac, Florida, Forente stater, 33321
- Pfizer Investigational Site
-
The Villages, Florida, Forente stater, 32159
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30309
- Pfizer Investigational Site
-
Canton, Georgia, Forente stater, 30114
- Pfizer Investigational Site
-
-
Illinois
-
Berwyn, Illinois, Forente stater, 60402
- Pfizer Investigational Site
-
Blue Island, Illinois, Forente stater, 60406
- Pfizer Investigational Site
-
Chicago, Illinois, Forente stater, 60611
- Pfizer Investigational Site
-
Chicago, Illinois, Forente stater, 60610
- Pfizer Investigational Site
-
DuQuoin, Illinois, Forente stater, 62832
- Pfizer Investigational Site
-
Evanston, Illinois, Forente stater, 60201
- Pfizer Investigational Site
-
Lake Forest, Illinois, Forente stater, 60045
- Pfizer Investigational Site
-
Marion, Illinois, Forente stater, 62959
- Pfizer Investigational Site
-
Pekin, Illinois, Forente stater, 61554
- Pfizer Investigational Site
-
Peoria, Illinois, Forente stater, 61603
- Pfizer Investigational Site
-
Peoria, Illinois, Forente stater, 61614
- Pfizer Investigational Site
-
-
Indiana
-
Beech Grove, Indiana, Forente stater, 46107
- Pfizer Investigational Site
-
Evansville, Indiana, Forente stater, 47710
- Pfizer Investigational Site
-
Fort Wayne, Indiana, Forente stater, 46805
- Pfizer Investigational Site
-
Fort Wayne, Indiana, Forente stater, 46825
- Pfizer Investigational Site
-
Jeffersonville, Indiana, Forente stater, 47130
- Pfizer Investigational Site
-
Scottsburg, Indiana, Forente stater, 47170
- Pfizer Investigational Site
-
-
Iowa
-
Des Moines, Iowa, Forente stater, 50314
- Pfizer Investigational Site
-
Iowa City, Iowa, Forente stater, 52242
- Pfizer Investigational Site
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160-7200
- Pfizer Investigational Site
-
Lathe, Kansas, Forente stater, 66061
- Pfizer Investigational Site
-
Overland Park, Kansas, Forente stater, 66213
- Pfizer Investigational Site
-
Wichita, Kansas, Forente stater, 67220
- Pfizer Investigational Site
-
-
Kentucky
-
Edgewood, Kentucky, Forente stater, 41017
- Pfizer Investigational Site
-
Erlanger, Kentucky, Forente stater, 41018
- Pfizer Investigational Site
-
Louisville, Kentucky, Forente stater, 40202
- Pfizer Investigational Site
-
-
Louisiana
-
Marrero, Louisiana, Forente stater, 70072
- Pfizer Investigational Site
-
New Orleans, Louisiana, Forente stater, 70112
- Pfizer Investigational Site
-
New Orleans, Louisiana, Forente stater, 70121
- Pfizer Investigational Site
-
-
Maine
-
Portland, Maine, Forente stater, 04102
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21218
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21205
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21287
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21201
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21204
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21208
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21224
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21228
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21229
- Pfizer Investigational Site
-
Baltimore, Maryland, Forente stater, 21237
- Pfizer Investigational Site
-
Bel Air, Maryland, Forente stater, 21014
- Pfizer Investigational Site
-
Westminster, Maryland, Forente stater, 21157
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- Pfizer Investigational Site
-
Boston, Massachusetts, Forente stater, 02215
- Pfizer Investigational Site
-
Burlington, Massachusetts, Forente stater, 1805
- Pfizer Investigational Site
-
-
Michigan
-
Dearborn, Michigan, Forente stater, 48126
- Pfizer Investigational Site
-
Detroit, Michigan, Forente stater, 48202
- Pfizer Investigational Site
-
Farmington Hill, Michigan, Forente stater, 48336
- Pfizer Investigational Site
-
Sterling Heights, Michigan, Forente stater, 48310
- Pfizer Investigational Site
-
West Bloomfield, Michigan, Forente stater, 48322
- Pfizer Investigational Site
-
-
Minnesota
-
Duluth, Minnesota, Forente stater, 55805
- Pfizer Investigational Site
-
Edina, Minnesota, Forente stater, 55435
- Pfizer Investigational Site
-
Maplewood, Minnesota, Forente stater, 55109
- Pfizer Investigational Site
-
Minneapolis, Minnesota, Forente stater, 55455
- Pfizer Investigational Site
-
St. Paul, Minnesota, Forente stater, 55102
- Pfizer Investigational Site
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64111
- Pfizer Investigational Site
-
St. Louis, Missouri, Forente stater, 63110
- Pfizer Investigational Site
-
St. Louis, Missouri, Forente stater, 63141
- Pfizer Investigational Site
-
St. Louis, Missouri, Forente stater, 63104
- Pfizer Investigational Site
-
St. Louis, Missouri, Forente stater, 63110-0205
- Pfizer Investigational Site
-
St. Louis, Missouri, Forente stater, 63117
- Pfizer Investigational Site
-
-
Nebraska
-
Papillion, Nebraska, Forente stater, 68046
- Pfizer Investigational Site
-
-
New Hampshire
-
Manchester, New Hampshire, Forente stater, 03102
- Pfizer Investigational Site
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08901
- Pfizer Investigational Site
-
-
New York
-
Albany, New York, Forente stater, 12208
- Pfizer Investigational Site
-
Brooklyn, New York, Forente stater, 11203
- Pfizer Investigational Site
-
Hawthorne, New York, Forente stater, 10535
- Pfizer Investigational Site
-
Manlius, New York, Forente stater, 13104
- Pfizer Investigational Site
-
New York, New York, Forente stater, 10021
- Pfizer Investigational Site
-
New York, New York, Forente stater, 10029
- Pfizer Investigational Site
-
New York, New York, Forente stater, 10032
- Pfizer Investigational Site
-
Rochester, New York, Forente stater, 14618
- Pfizer Investigational Site
-
Rochester, New York, Forente stater, 14607
- Pfizer Investigational Site
-
Rochester, New York, Forente stater, 14621
- Pfizer Investigational Site
-
Syracuse, New York, Forente stater, 13202
- Pfizer Investigational Site
-
Syracuse, New York, Forente stater, 13210
- Pfizer Investigational Site
-
Valhalla, New York, Forente stater, 10595
- Pfizer Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28803
- Pfizer Investigational Site
-
Durham, North Carolina, Forente stater, 27710
- Pfizer Investigational Site
-
Eden, North Carolina, Forente stater, 27288
- Pfizer Investigational Site
-
Winston-Salem, North Carolina, Forente stater, 27157
- Pfizer Investigational Site
-
-
Ohio
-
Beachwood, Ohio, Forente stater, 44122
- Pfizer Investigational Site
-
Cincinnati, Ohio, Forente stater, 45219
- Pfizer Investigational Site
-
Cincinnati, Ohio, Forente stater, 45229
- Pfizer Investigational Site
-
Cincinnati, Ohio, Forente stater, 45246
- Pfizer Investigational Site
-
Cleveland, Ohio, Forente stater, 44106-5038
- Pfizer Investigational Site
-
Cleveland, Ohio, Forente stater, 44195
- Pfizer Investigational Site
-
Columbus, Ohio, Forente stater, 43210
- Pfizer Investigational Site
-
Columbus, Ohio, Forente stater, 43221
- Pfizer Investigational Site
-
Kettering, Ohio, Forente stater, 45429-1221
- Pfizer Investigational Site
-
Lorain, Ohio, Forente stater, 44053
- Pfizer Investigational Site
-
Sandusky, Ohio, Forente stater, 44870
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Pfizer Investigational Site
-
Tulsa, Oklahoma, Forente stater, 74133
- Pfizer Investigational Site
-
Tulsa, Oklahoma, Forente stater, 74136-1920
- Pfizer Investigational Site
-
Tulsa, Oklahoma, Forente stater, 74136
- Pfizer Investigational Site
-
-
Oregon
-
Eugene, Oregon, Forente stater, 97401
- Pfizer Investigational Site
-
Portland, Oregon, Forente stater, 97210
- Pfizer Investigational Site
-
Portland, Oregon, Forente stater, 97216
- Pfizer Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18102
- Pfizer Investigational Site
-
Allentown, Pennsylvania, Forente stater, 18106-0880
- Pfizer Investigational Site
-
Lansdale, Pennsylvania, Forente stater, 19446
- Pfizer Investigational Site
-
Lehighton, Pennsylvania, Forente stater, 18235
- Pfizer Investigational Site
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Pfizer Investigational Site
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Pfizer Investigational Site
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Pfizer Investigational Site
-
Sellersville, Pennsylvania, Forente stater, 18960
- Pfizer Investigational Site
-
-
Rhode Island
-
Pawtucket, Rhode Island, Forente stater, 02860
- Pfizer Investigational Site
-
Providence, Rhode Island, Forente stater, 02906
- Pfizer Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29403
- Pfizer Investigational Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57105
- Pfizer Investigational Site
-
Sioux Falls, South Dakota, Forente stater, 57108
- Pfizer Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38104
- Pfizer Investigational Site
-
Memphis, Tennessee, Forente stater, 38105
- Pfizer Investigational Site
-
Memphis, Tennessee, Forente stater, 38119-5209
- Pfizer Investigational Site
-
Memphis, Tennessee, Forente stater, 38128
- Pfizer Investigational Site
-
Nashville, Tennessee, Forente stater, 37205
- Pfizer Investigational Site
-
Nashville, Tennessee, Forente stater, 37232-6300
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, Forente stater, 78756
- Pfizer Investigational Site
-
Dallas, Texas, Forente stater, 75246
- Pfizer Investigational Site
-
Dallas, Texas, Forente stater, 75235
- Pfizer Investigational Site
-
Dallas, Texas, Forente stater, 75390-9047
- Pfizer Investigational Site
-
Denton, Texas, Forente stater, 76204
- Pfizer Investigational Site
-
Houston, Texas, Forente stater, 77030
- Pfizer Investigational Site
-
Lackland AFB, Texas, Forente stater, 78236-5300
- Pfizer Investigational Site
-
San Antonio, Texas, Forente stater, 78229
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84124
- Pfizer Investigational Site
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05401
- Pfizer Investigational Site
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23249
- Pfizer Investigational Site
-
Richmond, Virginia, Forente stater, 23298
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, Forente stater, 98104
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53295
- Pfizer Investigational Site
-
-
-
-
-
Agen, Frankrike, 47000
- Pfizer Investigational Site
-
Bordeaux, Frankrike, 33000
- Pfizer Investigational Site
-
Brest, Frankrike, 29200
- Pfizer Investigational Site
-
Clermont-ferrand, Frankrike, 63003
- Pfizer Investigational Site
-
Lyon, Frankrike, 69003
- Pfizer Investigational Site
-
Marseille, Frankrike, 13915 Cedex 20
- Pfizer Investigational Site
-
Paris CEDEX 05, Frankrike, 75230
- Pfizer Investigational Site
-
Rennes, Frankrike, 35033
- Pfizer Investigational Site
-
Roubaix Cdx, Frankrike, 59056
- Pfizer Investigational Site
-
Strasbourg, Frankrike, 67091
- Pfizer Investigational Site
-
Toulouse, Frankrike, 31059
- Pfizer Investigational Site
-
Toulouse, Frankrike, 31400
- Pfizer Investigational Site
-
-
Cedex
-
Pessac, Cedex, Frankrike, 33604
- Pfizer Investigational Site
-
-
-
-
-
Cork, Irland
- Pfizer Investigational Site
-
Dublin, Irland, D8
- Pfizer Investigational Site
-
-
-
-
-
Bologna, Italia, 40138
- Pfizer Investigational Site
-
Bologna, Italia, 40139
- Pfizer Investigational Site
-
Cuneo, Italia, 12100
- Pfizer Investigational Site
-
Firenze, Italia, 50134
- Pfizer Investigational Site
-
Napoli, Italia, 80131
- Pfizer Investigational Site
-
Rome, Italia, 00184
- Pfizer Investigational Site
-
Udine, Italia, 33100
- Pfizer Investigational Site
-
-
-
-
-
's-Hertogenbosch, Nederland, 5211 NL
- Pfizer Investigational Site
-
Alkmaar, Nederland, 1815 JD
- Pfizer Investigational Site
-
Amersfoort, Nederland, 3818 ES
- Pfizer Investigational Site
-
Amsterdam, Nederland, 1105 AZ
- Pfizer Investigational Site
-
Breda, Nederland, 4818 CK
- Pfizer Investigational Site
-
Eindhoven, Nederland, 5623 EJ
- Pfizer Investigational Site
-
Enschede, Nederland, 7513 ER
- Pfizer Investigational Site
-
Groningen, Nederland, 9713 GZ
- Pfizer Investigational Site
-
Groningen, Nederland, 9728 NZ
- Pfizer Investigational Site
-
Leiden, Nederland, 2333 ZA
- Pfizer Investigational Site
-
Nieuwegein, Nederland, 3435 CM
- Pfizer Investigational Site
-
Nijmegen, Nederland, 6532 SZ
- Pfizer Investigational Site
-
Zwolle, Nederland, 8011 JW
- Pfizer Investigational Site
-
Zwolle, Nederland, 8025 AB
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Spania, 08035
- Pfizer Investigational Site
-
Barcelona, Spania, 08036
- Pfizer Investigational Site
-
Cordoba, Spania, 14004
- Pfizer Investigational Site
-
Madrid, Spania, 28007
- Pfizer Investigational Site
-
Madrid, Spania, 28041
- Pfizer Investigational Site
-
Madrid, Spania, 28029
- Pfizer Investigational Site
-
Madrid, Spania, 28040
- Pfizer Investigational Site
-
San Sebastian, Spania, 20014
- Pfizer Investigational Site
-
Santiago de Compostela, Spania, 15706
- Pfizer Investigational Site
-
Sevilla, Spania, 41013
- Pfizer Investigational Site
-
Sevilla, Spania, 41009
- Pfizer Investigational Site
-
Valladolid, Spania, 47011
- Pfizer Investigational Site
-
Zaragoza, Spania, 50009
- Pfizer Investigational Site
-
-
-
-
-
Barnet, Storbritannia, EN5 3DJ
- Pfizer Investigational Site
-
Glasgow, Storbritannia, G11 6NT
- Pfizer Investigational Site
-
London, Storbritannia, E1 1BB
- Pfizer Investigational Site
-
London, Storbritannia, NW3 2PF
- Pfizer Investigational Site
-
Paisley, Storbritannia, P1 1HR
- Pfizer Investigational Site
-
-
Essex
-
Romford, Essex, Storbritannia, RM7 OBE
- Pfizer Investigational Site
-
-
Greater London
-
London, Greater London, Storbritannia, E2 9JX
- Pfizer Investigational Site
-
London, Greater London, Storbritannia, NW10 7NS
- Pfizer Investigational Site
-
London, Greater London, Storbritannia, SW17 0RE
- Pfizer Investigational Site
-
-
Hampshire
-
Aldershot, Hampshire, Storbritannia, GU11 3RB
- Pfizer Investigational Site
-
-
Kent
-
Farnborough, Kent, Storbritannia, BR6 7AR
- Pfizer Investigational Site
-
-
Lancashire
-
Blackpool, Lancashire, Storbritannia, FY3 8NR
- Pfizer Investigational Site
-
-
Leicestershire
-
Leicester, Leicestershire, Storbritannia, LE3 9QP
- Pfizer Investigational Site
-
-
Middlesex
-
London, Middlesex, Storbritannia, HA8 0AD
- Pfizer Investigational Site
-
-
West Midlands
-
Coventry, West Midlands, Storbritannia, CV1 4FH
- Pfizer Investigational Site
-
Coventry, West Midlands, Storbritannia, CV2 2DX
- Pfizer Investigational Site
-
-
Wiltshire
-
Swindon, Wiltshire, Storbritannia, SN3 6BB
- Pfizer Investigational Site
-
-
-
-
-
Bern, Sveits, 3010
- Pfizer Investigational Site
-
Geneve 14, Sveits, CH-1211
- Pfizer Investigational Site
-
Lausanne, Sveits, CH-1011
- Pfizer Investigational Site
-
Lugano, Sveits, 6900
- Pfizer Investigational Site
-
St Gallen, Sveits, CH-9007
- Pfizer Investigational Site
-
-
-
-
-
Bloemfontein, Sør-Afrika, 9301
- Pfizer Investigational Site
-
Cape Town, Sør-Afrika, 7500
- Pfizer Investigational Site
-
Cape Town, Sør-Afrika, 7405
- Pfizer Investigational Site
-
Parow, Sør-Afrika, 7505
- Pfizer Investigational Site
-
-
Gauteng
-
Johannesburg, Gauteng, Sør-Afrika, 2193
- Pfizer Investigational Site
-
Sunninghill, Gauteng, Sør-Afrika, 2157
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Tyskland, 13353
- Pfizer Investigational Site
-
Berlin, Tyskland, 13439
- Pfizer Investigational Site
-
Essen, Tyskland, 45329
- Pfizer Investigational Site
-
Hamburg, Tyskland, 20246
- Pfizer Investigational Site
-
Schwerte, Tyskland, D-58239
- Pfizer Investigational Site
-
Tostedt, Tyskland, 21255
- Pfizer Investigational Site
-
Wurzburg, Tyskland, 97070
- Pfizer Investigational Site
-
-
-
-
-
Feldkirch, Østerrike, A-6807
- Pfizer Investigational Site
-
Oberpullendorf, Østerrike, A-7350
- Pfizer Investigational Site
-
Wien, Østerrike, A-1090
- Pfizer Investigational Site
-
Wien, Østerrike, 1100
- Pfizer Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
35 år til 75 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inklusjonskriterier:
Menn og kvinner i alderen 35-75 år som har tydelig CHD
Ekskluderingskriterier:
Kjent overfølsomhet for HMG CO-A reduktasebehandling, leversykdom, tegn på sekundær hyperlipidemi
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Det primære utfallet er tiden til forekomsten av en major
|
kardiovaskulær hendelse, definert som det sammensatte utfallet av
|
følgende kliniske endepunkter
|
CHD død
|
Ikke-dødelig/Ikke-prosedyrerelatert MI
|
Gjenopplivet hjertestans eller dødelig/ikke-dødelig hjerneslag
|
Sekundære resultatmål
Resultatmål |
---|
Forekomsten av følgende kliniske hendelser
|
Større koronarhendelse (CHD-død, ikke-dødelig hjerteinfarkt eller gjenopplivet hjertestans)
|
enhver koronarhendelse (større koronarhendelse eller CABG
|
PTCA, annen revaskulariseringsprosedyre, prosedyrerelatert hjerteinfarkt eller dokumentert angina)
|
cerebrovaskulær hendelse (dødelig eller ikke-dødelig hjerneslag, TIA)
|
perifer vaskulær sykdom; sykehusinnleggelse med primærdiagnose 'CHF
|
enhver kardiovaskulær hendelse (noen av de ovennevnte); og dødelighet av alle årsaker.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17.
- Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.
- Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. doi: 10.1161/CIRCOUTCOMES.118.004724.
- Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5.
- Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018 Aug 21;138(8):770-781. doi: 10.1161/CIRCULATIONAHA.117.032318.
- Ong KL, Waters DD, Fayyad R, Vogt L, Melamed S, DeMicco DA, Rye KA, Barter PJ. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc. 2018 Jan 22;7(2):e007387. doi: 10.1161/JAHA.117.007387.
- Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
- Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017 Apr 6;376(14):1332-1340. doi: 10.1056/NEJMoa1606148.
- Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648.
- Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.
- Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015 Apr 7;65(13):1286-1295. doi: 10.1016/j.jacc.2015.01.050.
- Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; Treating to New Targets (TNT) Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014 Dec 22;9(12):e114519. doi: 10.1371/journal.pone.0114519. eCollection 2014.
- Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14.
- Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524.
- Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F, Petrides F, Rye KA, DeMicco DA, Barter PJ, Kastelein JJ, Lambert G. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012 May 15;59(20):1778-84. doi: 10.1016/j.jacc.2011.12.043.
- Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24;125(16):1979-87. doi: 10.1161/CIRCULATIONAHA.111.088591. Epub 2012 Mar 29.
- Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, DeMicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, LaRosa JC, Pedersen TR, Kastelein JJ; TNT and IDEAL Investigators. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet. 2012 Feb 1;5(1):51-7. doi: 10.1161/CIRCGENETICS.111.960252. Epub 2011 Dec 1.
- Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011 Jan 4;57(1):63-9. doi: 10.1016/j.jacc.2010.06.052.
- Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3.
- Waters DD. Clinical insights from the Treating to New Targets trial. Prog Cardiovasc Dis. 2009 May-Jun;51(6):487-502. doi: 10.1016/j.pcad.2009.01.001.
- Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008 Aug;83(8):870-9.
- Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008 May 20;51(20):1938-43. doi: 10.1016/j.jacc.2007.12.054.
- Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.
- Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. doi: 10.1056/NEJMoa064278.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. april 1998
Primær fullføring
7. desember 2022
Studiet fullført
1. august 2004
Datoer for studieregistrering
Først innsendt
16. mai 2006
Først innsendt som oppfylte QC-kriteriene
16. mai 2006
Først lagt ut (Anslag)
18. mai 2006
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
3. mai 2007
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. mai 2007
Sist bekreftet
1. mai 2007
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Cerebrovaskulære lidelser
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Arteriosklerose
- Arterielle okklusive sykdommer
- Hjertesykdommer
- Slag
- Koronararteriesykdom
- Myokardiskemi
- Koronar sykdom
- Kardiovaskulære sykdommer
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antimetabolitter
- Antikolesteremiske midler
- Hypolipidemiske midler
- Lipidregulerende midler
- Hydroksymetylglutaryl-CoA-reduktasehemmere
- Atorvastatin
Andre studie-ID-numre
- 0981-117
- A2581136
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Atorvastatin
-
GlaxoSmithKlineFullførtDiabetes mellitus, type 2Korea, Republikken, Malaysia, Filippinene, Thailand, Den russiske føderasjonen, Mexico
-
Chong Kun Dang PharmaceuticalFullførtHøyt kolesterolKorea, Republikken
-
Obafemi Awolowo University Teaching HospitalOpen PhilanthropyRekruttering
-
Organon and CoFullført
-
Tanta UniversityFullført
-
Hippocration General HospitalFullførtKoronararteriesykdom | Aterosklerose | Endotelial dysfunksjon | Oksidativt stress | HMG-CoA-reduktasehemmer toksisitetHellas
-
PfizerFullførtHypertriglyseridemi | Hyperlipoproteinemi Type IVForente stater, Canada
-
Zhongda HospitalHar ikke rekruttert ennåAkutt iskemisk hjerneslag | Mekanisk trombektomiKina
-
St. Olavs HospitalUllevaal University Hospital; Oslo University Hospital; University Hospital... og andre samarbeidspartnereHar ikke rekruttert ennå
-
Beijing HospitalUkjent